Back to top
more

Alexion Pharmaceuticals, Inc. (ALXN)

(Delayed Data from NSDQ)

$136.69 USD

136.69
978,618

+3.56 (2.67%)

Updated May 3, 2019 04:00 PM ET

After-Market: $136.70 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks News

What's in Store for IDEXX Laboratories' (IDXX) Q4 Earnings?

IDEXX's (IDXX) is likely to report strong earnings for Q4, courtesy of a global surge in CAG Diagnostic revenues.

Nalak Das headshot

4 Top-Ranked Stocks Poised to Beat on Q4 Earnings Next Week

For fourth-quarter 2019, earnings trends are improving as companies are coming up with their reports.

Alexion Pharmaceuticals (ALXN) Reports Next Week: Wall Street Expects Earnings Growth

Alexion (ALXN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in Store for Align Technology's (ALGN) Q4 Earnings?

Align Technology (ALGN) is expected to have gained from continued adoption of Invisalign system in Q4.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for January 23rd

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for today:

3 Reasons Why Alexion (ALXN) Is a Great Growth Stock

Alexion (ALXN) could produce exceptional returns because of its solid growth attributes.

ALXN vs. QGEN: Which Stock Should Value Investors Buy Now?

ALXN vs. QGEN: Which Stock Is the Better Value Option?

5 Big Drug/Biotech Stocks Set to Trump Q4 Earnings Estimates

Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the fourth quarter.

Top Ranked Growth Stocks to Buy for January 22nd

Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, January 22nd.

Mersana Therapeutics (MRSN) Looks Good: Stock Adds 5.8% in Session

Mersana Therapeutics (MRSN) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for January 20th

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today.

Top Ranked Growth Stocks to Buy for January 20th

Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, January 20th

Alexion to Start Pivotal Study on Ultomiris for ALS in Q1

Alexion (ALXN) plans to initiate a phase III study on Ultomiris (ravulizumab) to treat amyotrophic lateral sclerosis.

Momenta (MNTA) Provides Pipeline Updates, Stock Rallies

Shares of Momenta (MNTA) rise 23.7% on pipeline updates.

Alexion Pharmaceuticals (ALXN) Dips More Than Broader Markets: What You Should Know

Alexion Pharmaceuticals (ALXN) closed at $112.79 in the latest trading session, marking a -0.99% move from the prior day.

Ultragenyx Provides Preliminary Crysvita 2019 Revenues

Ultragenyx (RARE) provides preliminary 2019 revenue numbers and 2020 outlook for Crysvita, along with other pipeline updates.

Alnylam Provides Preliminary Q4 Sales for Onpattro & Givlaari

Alnylam (ALNY) announces preliminary results for the fourth quarter and 2019 and provides other updates.

Ultragenyx's Gene Therapy Positive in Genetic Disorder Study

Shares of Ultragenyx (RARE) rise 23.4% after releasing positive top-line data from the phase I/II study of its gene therapy candidate DTX301 for the treatment of OTC deficiency.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for January 13th

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for today:

Top Ranked Growth Stocks to Buy for January 13th

Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, January 13th.

Gilead (GILD) Inks License Deal with Xencor for HIV Candidate

Gilead Sciences (GILD) entered into a technology license agreement with Xencor for use of XmAb antibody technologies in investigational agents for HIV.

Has Alexion Pharmaceuticals (ALXN) Outpaced Other Medical Stocks This Year?

Is (ALXN) Outperforming Other Medical Stocks This Year?

The Zacks Analyst Blog Highlights: H&R Block, Berry Global Group, Emergent BioSolutions, Pilgrim's Pride and Alexion Pharmaceuticals

The Zacks Analyst Blog Highlights: H&R Block, Berry Global Group, Emergent BioSolutions, Pilgrim's Pride and Alexion Pharmaceuticals

Incyte's Application for Pemigatinib Gets EMA's Validation

The EMA endorses Incyte's (INCY) MAA for pemigatinib to treat locally advanced/metastatic cholangiocarcinoma with a FGFR2 fusion that is relapsed or refractory post minimum one line of systemic therapy.

Amarin Posts '19 Preliminary Results, Gives 2020 Expense View

Amarin's (AMRN) Vascepa sales witness strong growth. The trend is anticipated to continue in 2020. However, the operating expense guidance for 2020 was higher than expected, which probably pulled the stock down.